Medicine
Luxturna kit
Luxturna kit is a prescription medicine containing Voretigene neparvovec, marketed by Spark Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store LUXTURNA and Diluent frozen at ≤ -65 °C. Following thaw of the vials…
Key facts
- Active ingredient (INN)
- Voretigene neparvovec
- Brand
- Luxturna
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Spark Therapeutics
- Manufacturer
- Spark Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store LUXTURNA and Diluent frozen at ≤ -65 °C. Following thaw of the vials, store at room temperature. Store diluted LUXTURNA at room temperature.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01XA27 Voretigene neparvovec
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 December 2017
- Identifiers
- RxCUI 1995884, 1995886DailyMed set ID 08313a24-e7ce-457a-bb3f-161bc45517eeNDC 71394-415Application BLA125610
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 1 injection, suspension in 1 vial, plastic * 1 injection, solution in 1 vial, plastic | 71394-415-01 | Spark Therapeutics | 19 December 2017 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Voretigene neparvovec is a prescription medicine indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It is available as kits. MedsAcross supplies Voretigene neparvovec for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Voretigene neparvovecFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LUXTURNA prescribing information (Spark Therapeutics) · U.S. National Library of Medicine, DailyMed
- Luxturna: European public assessment report (EPAR) · European Medicines Agency
Need Luxturna kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.